Induced pluripotent stem cells are experiencing strong growth
due to rising research into disease models and drug
discovery.
WILMINGTON, Del. , July 11,
2024 /PRNewswire/ -- The global induced
pluripotent stem cells industry was worth US$ 1.7 billion in 2023. By 2034, it is
estimated to reach US$ 4.6
billion, expanding at a CAGR of
9.4% between 2024 and 2034. As reprogramming strategies
improve, iPSCs become more feasible for many applications and more
attractive to buyers.
The utilization of iPSCs in drug discovery and disease modeling
is being accelerated by excessive-throughput screening
technologies. Aside from heart disease, liver failure, and
diabetes, iPSCs are capable of creating organ replacements. By
doing so, the donor organ shortage can be addressed and the impact
on affected people can be enhanced. Several wound recuperation
treatments are possible with iPSCs, including those that treat
excessive burns and chronic ulcers.
Cells from iPSCs can be used to develop new immunotherapies,
such as CAR-T mobile treatments for cancer. Depending on the
patient's immune system, these treatment plans may enhance
effectiveness and reduce side effects. Besides Parkinson's
disorder, spinal cord injuries, and macular degeneration, iPSCs can
also be used to update damaged or diseased cells.
Download Sample of the
Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30530
Induced Pluripotent Stem Cells Market Report
Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 1.7 Bn
|
Forecast (Value) in
2034
|
US$ 4.6 Bn
|
Growth Rate
(CAGR)
|
9.4 %
|
No. of
Pages
|
156 Pages
|
Segments
covered
|
By Cell Type, By
Application, By End-user
|
Global Induced Pluripotent Stem Cells Market:
Competitive Landscape
iPSC-based therapies can be commercialized more quickly with
partnerships among educational institutions and
biotech/pharmaceutical companies. By utilizing global studies
networks and consortia, information can be shared, protocols are
standardized, and problems can be collectively solved, propelling
forward the iPSC industry.
Key Players Profiled
- Axol Bioscience
- Cynata Therapeutics Limited
- Evotec SE
- Fate Therapeutics
- FUJIFILM Cellular Dynamics Inc.
- Ncardia
- LizarBio Therapeutics
- REPROCELL Global
- Sumitomo Dainippon Pharma Company Limited
- Takara Bio USA Inc.
- Thermo Fisher Scientific
- Vertex Pharmaceuticals
Key Developments
- In May 2023, Fujifilm Cellular
Dynamics, a global provider of induced pluripotent stem cells
(iPSC), and Novo Nordisk signed an agreement to jointly develop
and commercialize iPSC-derived cell therapies targeting serious
chronic conditions.
- In October 2023, Axol
Bioscience and Sygnature Discovery were involved in a scientific
collaboration to incorporate human induced pluripotent stem
cells-derived microglia into vitroscreening workflows for
high-content imaging.
Key Findings of the Market Report
- As of 2023, diagnostic centers held the largest share of the
market.
- In 2023, North America held
the dominant position in the market.
- In terms of cell type, fibroblasts are likely to be the primary
driver of induced pluripotent stem cell demand.
- The use of stem cells for regenerative medicine is expected to
increase in the near future.
- A growing number of pharmaceutical and biotechnology companies
are expected to expand their offerings.
Global Induced Pluripotent Stem Cells Market: Growth
Drivers
- The development of gene-enhancing technologies, including
CRISPR-Cas9, has improved the production and precision of iPSCs
significantly. By using these technologies, genetic defects can be
corrected, and illness fashions can be introduced.
- In recent years, technology has improved the ease and safety of
converting somatic cells into iPSCs, allowing them to be used in
medical procedures. Manufacturing and analyzing iPSCs have been
streamlined by automation and high-throughput screening technology,
enabling big-scale research and cutting costs.
- The iPSCs are crucial to growing regenerative therapies for
damaged tissues and organs. A capacity solution has been developed
for coronary heart disease, spinal cord injuries, and
neurodegenerative diseases. In oncology and chronic illness
management, iPSCs can be derived from a patient's own cells to
minimize the chance of immune rejection.
- Using iPSCs, researchers can build disease-specific mobile
models, allowing them to study disease mechanisms and screen
potential drugs more effectively. Using iPSCs reduces the reliance
on animal models and improves the predictability of human responses
to toxicology.
Explore Sample of the
Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=30530
Global Induced Pluripotent Stem Cells Market: Regional
Landscape
- North America has numerous
international-renowned research institutions and universities that
are at the leading edge of stem cell studies. IPSCs are
used in basic studies, drug discovery, and disease modeling by
these establishments. The National Institutes of Health (NIH)
together with government groups provide significant funding for
research on iPSCs.
- iPSCs have been the subject of an excessive number of
clinical trials throughout North
America, indicating their ability to grow new
therapies. Several successful trials and future cures are
expected to increase demand. A stem cell bank or repository in the
status quo facilitates the use of iPSCs for therapeutic and
research purposes.
- The iPSC is a viable alternative to embryonic stem cells
that bypasses many of the ethical issues associated with embryonic
stem cells. Increasing public awareness about stem cell
research and its benefits increases support for iPSC-based
improvements.
Global Induced Pluripotent Stem Cells Market:
Segmentation
Cell Type
- Hepatocytes
- Fibroblasts
- Keratinocytes
- Others (Neurons, etc.)
Application
- Drug Development
- Regenerative Medicine
- Toxicity Testing
- Tissue Engineering
- Cell Therapy
- Disease Modeling
End User
- Hospitals
- Diagnostic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Others (Academic & Research Institutes, etc.)
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research
Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=30530<ype=S
More Trending Report by Transparency Market Research:
- Geriatric Care Services Market to Grow at a 7.3% CAGR
from 2023 to 2028, reaching US$ 0.7
billion: TMR Report
- Preeclampsia Diagnostics Market Set to Reach
USD 2.3 Billion by 2031, growing
at a CAGR of 3.8%: TMR Report
- Medical Case Management Market is expected to grow at a
CAGR of 6.1% from 2024 to 2034 and reach US$ 12.3 Bn by the end of 2034.
- Lucid Dreaming Devices Market is expected to grow at a
CAGR of 5.1% from 2024 to 2034 and reach US$ 196.8 Mn by the end of 2034.
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter
| Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/induced-pluripotent-stem-cells-market-size-is-expected-to-grow-at-a-cagr-of-9-4-and-reach-usd-4-6-billion-by-2034-transparency-market-research-inc-302194815.html
SOURCE Transparency Market Research